BRPI0312002B8 - composição para solubilização de paclitaxel e método de preparação da mesma - Google Patents

composição para solubilização de paclitaxel e método de preparação da mesma

Info

Publication number
BRPI0312002B8
BRPI0312002B8 BRPI0312002A BRPI0312002A BRPI0312002B8 BR PI0312002 B8 BRPI0312002 B8 BR PI0312002B8 BR PI0312002 A BRPI0312002 A BR PI0312002A BR PI0312002 A BRPI0312002 A BR PI0312002A BR PI0312002 B8 BRPI0312002 B8 BR PI0312002B8
Authority
BR
Brazil
Prior art keywords
paclitaxel
composition
weight
solubilization
preparation
Prior art date
Application number
BRPI0312002A
Other languages
English (en)
Inventor
Chung Hesson
Jeong Seo-Young
Kwon Ick-Chan
Park Yeong-Taek
Lee In-Hyun
Yuk Soon-Hong
Choi Young-Wook
Park Jae-Hyung
Chung Jin-Wook
Original Assignee
Korea Inst Sci & Tech
Daehwa Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36386602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0312002(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Korea Inst Sci & Tech, Daehwa Pharm Co Ltd filed Critical Korea Inst Sci & Tech
Publication of BRPI0312002B8 publication Critical patent/BRPI0312002B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIÇÃO PARA SOLUBILIZAÇÃO DE PACLITAXEL E MÉTODO DE PREPARAÇÃO DA MESMA". A presente invenção refere-se a uma composição de paclitaxel e aos métodos de preparação da mesma para solubilizar o paclitaxel onde a referida composição compreende 4-90% em peso de pelo menos um selecionado dos monoglicerídeos, 0,01-90% em peso de pelo menos um óleo e 0,01-20% em peso de paclitaxel. A presente invenção também refere-se a uma composição de paclitaxel incluindo emulsificantes e aos métodos de preparação da mesma para solubilizar o paclitaxel onde a referida composição compreende 4-90% em peso de pelo menos um selecionado dos monoglicerídeos, 0,01-90% em peso de pelo menos um óleo, 0,01-90% em peso de pelo menos um emulsificante e 0,01-20% em peso de paclitaxel. A composição da presente invenção é um sistema de distribuição de paclitaxel eficaz uma vez que a composição solubiliza o paclitaxel, não forma agregados depois ser dispersada em água, adsorve bem na parede intestinal, e portanto tem alta biodisponibilidade.
BRPI0312002A 2002-07-20 2003-07-18 composição para solubilização de paclitaxel e método de preparação da mesma BRPI0312002B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2002-0042791A KR100533458B1 (ko) 2002-07-20 2002-07-20 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
PCT/KR2003/001427 WO2004009075A1 (en) 2002-07-20 2003-07-18 Composition for solubilization of paclitaxel and preparation method thereof

Publications (1)

Publication Number Publication Date
BRPI0312002B8 true BRPI0312002B8 (pt) 2022-10-18

Family

ID=36386602

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0312002-3A BRPI0312002B1 (pt) 2002-07-20 2003-07-18 Composition for solubilization of paclitaxel and method of preparing the same
BRPI0312002A BRPI0312002B8 (pt) 2002-07-20 2003-07-18 composição para solubilização de paclitaxel e método de preparação da mesma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0312002-3A BRPI0312002B1 (pt) 2002-07-20 2003-07-18 Composition for solubilization of paclitaxel and method of preparing the same

Country Status (12)

Country Link
US (1) US8075917B2 (pt)
EP (1) EP1545499B1 (pt)
JP (1) JP4744875B2 (pt)
KR (1) KR100533458B1 (pt)
CN (1) CN100544714C (pt)
AU (1) AU2003281465A1 (pt)
BR (2) BRPI0312002B1 (pt)
CA (1) CA2493336C (pt)
HK (1) HK1082674A1 (pt)
RU (1) RU2291693C2 (pt)
WO (1) WO2004009075A1 (pt)
ZA (1) ZA200409126B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181810A1 (en) * 2002-03-25 2003-09-25 Murphy Kieran P. Kit for image guided surgical procedures
US9375203B2 (en) 2002-03-25 2016-06-28 Kieran Murphy Llc Biopsy needle
US7927368B2 (en) * 2002-03-25 2011-04-19 Kieran Murphy Llc Device viewable under an imaging beam
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
JP2008519076A (ja) * 2004-11-02 2008-06-05 テルアビブ ユニバーシティ フューチャー テクノロジー デベロップメント エル．ピー． 脂質化グリコサミノグリカン粒子中の水不溶性又は水難溶性薬物の処方、並びに診断及び治療のためのこれらの使用
EP1787645A1 (en) * 2005-11-18 2007-05-23 Institut Curie New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway
KR100737742B1 (ko) * 2005-12-05 2007-07-10 대화제약 주식회사 파클리탁셀 조성물의 제조 방법
CN101006997B (zh) * 2006-01-26 2011-07-20 董英杰 复方紫杉醇及衍生物多西他赛脂肪乳剂和制备方法
CA2664641A1 (en) 2006-09-26 2008-04-10 Astellas Pharma, Inc. Controlled release dosage form of tacrolimus
CA2674039A1 (en) 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
WO2008098415A1 (fr) * 2007-02-14 2008-08-21 Beijing Century Biocom Pharmaceutical Technology Co., Ltd. Composition pharmaceutique contenant du taxane et son procédé de préparation et d'application
JP5135852B2 (ja) * 2007-03-30 2013-02-06 日油株式会社 可溶化用組成物
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
CN101785757B (zh) * 2009-01-22 2012-02-22 美迪思生物科技(北京)有限公司 一种紫杉醇自乳化制剂及其制备方法和用途
CN101926757B (zh) 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
EP2715359A4 (en) * 2011-05-30 2015-01-21 String Therapeutics Inc METHODS AND COMPOSITIONS FOR THE MONITORING AND DOSED ADMINISTRATION OF A THERAPEUTIC MEDICINE BY PHARMACO-KINETIC PROFILING ON PLACES OF CARE
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2791604T3 (es) * 2012-07-16 2020-11-05 Ct Disease Contr & Prevention Kits de detección de lectura directa para contaminación de superficie por fármacos antineoplásicos
US9018246B2 (en) 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2951284A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
ES2524248B2 (es) * 2014-08-01 2015-07-03 Lvd Biotech S.L. Balón liberador de paclitaxel y procedimiento de fabricación del mismo
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
ES2895948T3 (es) * 2015-07-30 2022-02-23 Dae Hwa Pharma Co Ltd Composición farmacéutica para administración oral que comprende taxano a alta concentración
KR101612257B1 (ko) * 2015-07-30 2016-04-20 대화제약 주식회사 고농도의 탁산을 포함하는 경구 투여용 약학 조성물
WO2017049083A2 (en) * 2015-09-16 2017-03-23 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3026108A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use
CN106620717B (zh) * 2016-12-13 2020-11-24 上海交通大学 一种具有逆转肿瘤多药耐药性功能的两亲性缀合物抗肿瘤纳米药及其制备方法和应用
WO2018159941A1 (ko) * 2017-03-02 2018-09-07 대화제약 주식회사 자나미비르를 포함하는 안정한 약제학적 조성물
KR101991661B1 (ko) * 2017-03-02 2019-06-21 대화제약 주식회사 자나미비르를 포함하는 안정한 약제학적 조성물
KR102658256B1 (ko) 2017-03-15 2024-04-16 디에프비 소리아, 엘엘씨 탁산 나노입자를 사용한 피부 악성 종양의 치료용 국소 요법
US11254773B2 (en) 2017-05-11 2022-02-22 The Regents Of The University Of California Nanoscale multiple emulsions and nanoparticles
EP3765035A4 (en) 2018-03-16 2021-10-27 DFB Soria, LLC TOPICAL THERAPY FOR TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND ETERNAL CANCER USING TAXANNANO PARTICLES
KR20200005110A (ko) * 2018-07-05 2020-01-15 대화제약 주식회사 탁산-함유 약학 조성물을 함유하는 의약품의 안정성 개선방법
KR102093100B1 (ko) * 2018-07-11 2020-03-26 대화제약 주식회사 산화 안정성이 향상된 탁산을 포함하는 경구용 약학 조성물
KR20210078505A (ko) * 2018-10-16 2021-06-28 유에스 나노 푸드 앤 드럭 인코포레이티드 종양내 주사 제형
CN109821055A (zh) * 2019-02-01 2019-05-31 厦门大学 一种药物-碘油溶剂及其制备方法
KR20200142943A (ko) * 2019-06-14 2020-12-23 대화제약 주식회사 항바이러스제를 포함하는 분말 제제 형태의 경구투여용 약학 조성물
KR102185475B1 (ko) 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
CN110302434A (zh) * 2019-07-14 2019-10-08 大连医科大学 一种易于推注的碘化油栓塞剂及其制备方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN113244254B (zh) * 2021-03-26 2023-03-14 浙江工业大学 一种增强金黄霉素a水溶性的组合物及其制备与应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
JPH0629180B2 (ja) * 1986-06-16 1994-04-20 エーザイ株式会社 吸収性の改良されたメナテトレノン含有組成物
EP0448091B1 (en) * 1990-03-23 1998-08-05 The Green Cross Corporation Pharmaceutical composition containing slightly water-soluble drug
JPH06509577A (ja) * 1991-07-26 1994-10-27 スミスクライン・ビーチャム・コーポレイション Ｗ／ｏミクロエマルジョン
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
SI0999826T1 (en) * 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US6121313A (en) * 1997-07-29 2000-09-19 Pharmacia & Upjohn Company Pharmaceutical composition in a form of self-emulsifying formulation for lipophilic compounds
CA2322428C (en) * 1998-04-01 2006-12-05 Mattel, Inc. Toy vehicle jumpset with crossing rise and descent paths
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
IL146567A0 (en) * 1999-06-04 2002-07-25 Skyepharma Inc Oil-core particles containing a hydrophobic core material and hydrophobic drug and method for the preparation thereof
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
AR027714A1 (es) * 2000-03-24 2003-04-09 Baker Norton Pharma Uso de sales metalicas para estabilizar composiciones de taxanos.
JP3448006B2 (ja) * 2000-03-29 2003-09-16 独立行政法人食品総合研究所 機能性エマルション
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
MXPA03006404A (es) * 2001-01-18 2004-12-02 Upjohn Co Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
KR20040066921A (ko) 2001-12-20 2004-07-27 브리스톨-마이어스스퀴브컴파니 생체이용률이 향상된 경구 활성 탁산 유도체의 제약조성물
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
KR100573289B1 (ko) * 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법

Also Published As

Publication number Publication date
EP1545499A4 (en) 2009-11-18
CA2493336C (en) 2009-11-24
JP2005538090A (ja) 2005-12-15
AU2003281465A1 (en) 2004-02-09
US8075917B2 (en) 2011-12-13
US20060104999A1 (en) 2006-05-18
WO2004009075A1 (en) 2004-01-29
KR20040009015A (ko) 2004-01-31
EP1545499A1 (en) 2005-06-29
JP4744875B2 (ja) 2011-08-10
CA2493336A1 (en) 2004-01-29
ZA200409126B (en) 2005-06-29
RU2291693C2 (ru) 2007-01-20
CN1671370A (zh) 2005-09-21
BRPI0312002B1 (pt) 2017-11-28
KR100533458B1 (ko) 2005-12-07
CN100544714C (zh) 2009-09-30
RU2005104567A (ru) 2005-07-10
EP1545499B1 (en) 2013-02-20
BR0312002A (pt) 2005-05-03
HK1082674A1 (en) 2006-06-16

Similar Documents

Publication Publication Date Title
BRPI0312002B8 (pt) composição para solubilização de paclitaxel e método de preparação da mesma
Qureshi et al. Novel tocotrienols of rice bran inhibit atherosclerotic lesions in C57BL/6 ApoE-deficient mice
BR0304134A (pt) Métodos para produção de fluidos de tratamento e de fraturamento, para tratar e para fraturar uma formação subterrânea, e para realizar uma pluralidade de tratamentos de formação subterrânea, e, composição para um fluido de tratamento
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
BRPI0506461A (pt) método implementado por computador para executar em um computador um sistema de computação de múltiplos agentes baseado no comportamento, sistema de computação de múltiplos agentes baseado no comportamento, mìdia que se pode ser lida por computador e programa de computador em uma mìdia que pode ser lida por computador
MX2020012041A (es) Formulacion farmaceutica.
UY27165A1 (es) 6,7,8,9-tetrahidro-5h-benzocicolheptenil aminas aciladas y su uso como farmacos
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
BR0307524A (pt) Composição farmacêutica para inibidores de protease viral de hepatite c
BRPI0505095A (pt) sistema e método para anúncio em linha e fora de linha de conteúdo entregue a uma tela de exibição
ECSP034620A (es) Mezclas o compuestos organicos para el tratamiento de enfermedades de las vias respiratorias
UY30712A1 (es) Nuevos derivados de 1, 4-benzotiepina-1, 1-dioxido sustituidos con fluor, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
ATE320259T1 (de) Verwendung von oestrogenverbindungen zur steigerung der libido bei frauen
NO2016012I2 (no) Betulin (bjørkeneverekstrakt)
BRPI0517313A (pt) composição contendo óleo, artigo de consumo, método para conferir, intensificar, melhorar ou modificar propriedades, processo para a preparação de uma composição, e, sistema para a solubilização de óleo
BR112021020359A2 (pt) Composição autoemulsificante de fármaco de polifenol de flavonoide, método de preparação da mesma, composição farmacêutica da mesma e aplicação da mesma
BRPI0608061A2 (pt) método para abaixar os nìveis no sangue circulante de um lipìdio selecionado do grupo que consiste em colesterol ldl, triglicerìdios, colesterol total, e as misturas destes e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons
BR9912024A (pt) Emplastros em gel contento esteróide e processo para a produção dos mesmos
Burlet et al. Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis
KR950016735A (ko) 터너 증후군의 억제 방법
Hunneyball et al. Pharmacological studies of antigen-induced arthritis in BALB/c mice II. The effects of second-line antirheumatic drugs and cytotoxic agents on the histopathological changes
Madsen et al. 4-tert-octylphenol and 17β-estradiol applied by feeding to flounder Platichthys flesus: induction of vitellogenin and accumulation in tissues
EA200200217A1 (ru) Парентеральная цисплатиновая эмульсия
BR0312817A (pt) Composição de pomada oftálmica compreendendo uma droga, uma base de pomada e um agente solubilizante/dispersante

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DAEHWA PHARM. CO., LTD. (KR)

Free format text: TRANSFERIDO DE: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/337; A61P 35/00

Ipc: A61K 31/337 (2011.01), A61P 35/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted
B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF